Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    AXIM
Previous Study | Return to List | Next Study

A Bioavailability Study on Dronabinol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03098940
Recruitment Status : Unknown
Verified March 2017 by Axim Biotechnologies.
Recruitment status was:  Not yet recruiting
First Posted : April 4, 2017
Last Update Posted : April 4, 2017
Information provided by (Responsible Party):
Axim Biotechnologies

Brief Summary:
This study is a two part study

Condition or disease Intervention/treatment Phase
THC Drug: Chewing Gum Phase 1

Detailed Description:
This study is a two part, open label, randomized, four periods cross-over study with a washout of at least 1 week between subsequent dosing occasions

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Two Part, Open Label, Randomized, Four Period Cross-over Study to Compare the Bioavailability of Two Different Dronabinol Formulations in Healthy Male and Female Volunteers
Estimated Study Start Date : January 2018
Estimated Primary Completion Date : April 2018
Estimated Study Completion Date : September 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Dronabinol

Arm Intervention/treatment
Experimental: Chewing gum
Chewing gum with various doses of dronabinol
Drug: Chewing Gum
During the study healthy subjects will receive single doses of the various strengths of dronabinol

Active Comparator: Capsule (Marinol)
Marinol is a product manufactured by AbbVie Capsule with various strengths of Marinol
Drug: Chewing Gum
During the study healthy subjects will receive single doses of the various strengths of dronabinol

Primary Outcome Measures :
  1. Bioequivalence [ Time Frame: up to 48 hours post-dose ]
    based on Peak Plasma Concentration (Cmax)

  2. Bioequivalence [ Time Frame: up to 48 hours post-dose ]
    based on Area under the plasma concentration versus time curve (AUC)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy, non-smoking male and female subject, aged between 18 and 55 year of age (inclusive) with a BMI ≥18.0 kg/m2 and ≤ 30.0 kg/m2.

Exclusion Criteria:

  • Smokers
Layout table for additonal information
Responsible Party: Axim Biotechnologies Identifier: NCT03098940    
Other Study ID Numbers: MedChew
First Posted: April 4, 2017    Key Record Dates
Last Update Posted: April 4, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No